• Profile
Close

Levetiracetam pharmacokinetics in critically ill patients undergoing renal replacement therapy

Journal of Critical Care Nov 06, 2020

Chappell K, Kimmons LA, Haller JT, et al. - The present study was conducted to ascertain the clearance of levetiracetam in patients requiring continuous renal replacement therapy (CRRT) or sustained low-efficiency dialysis (SLED). Researchers included adult individuals with acute kidney injury or end-stage renal disease needing either CRRT or SLED and levetiracetam for inclusion. They collected simultaneous arterial, venous, and effluent samples for analysis of levetiracetam concentrations every two hours for up to 6–8 h. They estimated levetiracetam clearance and half-life (t1/2) for each modality. This study was completed by eight CRRT patients and 4 SLED patients: 67% male, mean age 50 ± 13 years, and 83% had acute kidney injury. The findings revealed that levetiracetam clearance was substantial with both modalities under the operating conditions reported. The outcomes illustrated that there is the potential for subtherapeutic concentrations with currently recommended dosing strategies that account only for kidney function and not these extracorporeal routes of elimination.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay